Latest News
|
|
|
Medusa®
|
|
A Versatile Nano Carrier for the Delivery of Native Proteins
Medusa®, a self-assembled poly-aminoacid nanoparticles system, is a versatile protein carrier for the development of novel and second-generation long-acting native protein drugs. more info
|
Micropump® Technologies
|
From Pediatric to Geriatric Uses
Controlled-release systems permitting either extended (Micropump® I) or both delayed and extended (Micropump® II) delivery of small molecule drugs.
more info
|
|
Latest News
Latest Conference calls
Annual Reports
Annual Report 2009
Annual Report 2006 (PDF)
Annual Report 2005 (PDF)
Annual Report 2007 (PDF)
Annual Report 2008 (PDF)
Annual Report 2008 with 20-F (PDF)
Flamel Technologies Corporate Presentation - July 2010
To view the latest presentation, click here.
Financial Summary
| |
3 months ended June 30, 2010 ($000) |
| Total Revenue |
7,515 |
| Total Costs and Expenses |
(12,243) |
| Profit/(loss) from operations |
(4,728) |
| Net loss |
(4,290) |
|
| Cash and Marketable Securities Position |
$ 33.7 MM |
| Diluted EPS |
($ 0.18) |
| Basic shares outstanding |
24.41 MM |
Contact
Charles Marlio
Director of Strategic Planning and Investor Relations
33 avenue du Dr. Georges Levy
69693 Venissieux Cedex
France
Phone: (+33) 472-783-423
marlio@flamel.com
Frederick Simonin
Marketing analyst
33 avenue du Dr. Georges Levy
69693 Venissieux Cedex
France
simonin@flamel.com
|